GlassScriptPhysician profile
John D Venuti
NPI 1487668398
$6,839.77
in general payments reported to CMS, 2019-2025
30 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $2,200 · 2021: $578 · 2022: $353 · 2023: $234 · 2024: $701 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Consulting Fee: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.45 |
| Consulting Fee | $338.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,721.78 | 2020-2021 | |
| Novo Nordisk INC | $697.74 | 2019-2024 | |
| Amgen INC. | $665.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $588.92 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $508.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $342.73 | 2019-2020 | |
| Zoll Medical Corporation | $338.33 | 2025 | Defibrillator |
| Pfizer INC. | $337.20 | 2019-2020 | |
| Lilly USA, LLC | $250.04 | 2019-2025 | Zepbound |
| Astellas Pharma US INC | $223.71 | 2019-2021 | |
| Medtronic, INC. | $140.24 | 2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $107.93 | 2019 | |
| Merck Sharp & Dohme LLC | $95.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.66 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $86.69 | 2019-2025 | Rexulti |
| Abbott Laboratories | $76.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.07 | 2019 | |
| Radius Health, INC. | $52.19 | 2019 | |
| Amarin Pharma, INC. | $45.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2019 | |
| Exact Sciences Corporation | $31.06 | 2025 | The Cologuard Plus Collection Kit |
| Nalpropion Pharmaceuticals LLC | $27.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.43 | 2019 | |
| Sanofi Pasteur INC. | $26.60 | 2019 | |
| Kaleo, INC. | $26.26 | 2019 | |
| Alkermes, INC. | $13.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Venuti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.